Just Published: "Analgesics in Italy"

Analgesics sales benefited from a number of factors in 2015 as the category increased by 2% in current value. There are higher levels of stress among the Italian population, which can be linked to the increasingly hectic lifestyles among the Italian population, which are causing more people to suffer from headaches and migraines. According to industry sources, over six million people living in Italy regularly suffer from headaches, which suggests over a million of incidences of headaches on a daily basis, half of which could be treated with analgesics. In addition, sales of analgesics are being boosted by the success of recent new product launches and product switches, which has been able to meet the increasing demand for convenient formats and quicker results. Examples include the recently launched okitask, a ketoprofen-based analgesic which can be consumed on-the-go, and Tachipirina Flash Tab.

Full Report Details at
- http://www.fastmr.com/prod/1097817_analgesics_italy.aspx?afid=301

Competitive Landscape

Aziende Chimiche Riunite Angelini Francesco (Angelini) remained the leading player in Analgesics in 2015 with a value share of 31%, thanks mainly to its flagship analgesics brand Tachipirina and the Moment brand, which are the most popular analgesics in Italy, commonly taken for cases of fever and headaches and migraines respectively. Angelini is followed by Novartis Consumer Health, accounting for 24% of value sales in the category in 2015 thanks to its popular Voltaren and Voltadol brands, whilst Bayer ranked third with a value share of 9% thanks to Aspirina and Saridon brands.

Industry Prospects

Analgesics is set to continue capitalising on the increasingly hectic lifestyles of many Italian consumers over the forecast period as high level of stress are often linked to tension headaches. Consumers are expected to demand more convenient and quicker pain relief options during the forecast period as become increasingly willing to pay for premium products at a time when the Italian economy is expected to recover. It is likely that analgesics will experience more polarisation during the forecast period, to the benefit pricier references offering on-the-go formats and fast relief on the one hand, and cheaper options such as private label analgesics on the other. Moreover, private label is expected to continue gaining further value share in analgesics in Italy over the forecast period considering the relatively recent entrance of these products.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Italy with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Analgesics in Japan
- Analgesics in Denmark
- Analgesics in the United Kingdom
- Analgesics in Russia
- Analgesics in Sweden